Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions

Blood

Volumn 104, Issue 3, 2004, Pages 795-801

  Kohlhammer, Holger ^b   Schwaenen, Carsten ^b   Wessendorf, Swen ^b   Holzmann, Karlheinz ^b   Kestler, Hans A ^b   Kienle, Dirk ^b   Barth, Thomas F E ^b   Möller, Peter ^b   Ott, German ^b   Kalla, Jörg ^b   Radlwimmer, Bernhard ^b   Pscherer, Armin ^b   Stilgenbauer, Stephan ^b   Döhner, Hartmut ^b   Lichter, Peter ^b   Bentz, Martin ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; BASE PAIRING; CHROMOSOME 10P; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 8P; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; COMPARATIVE GENOMIC HYBRIDIZATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 3242762286     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4175     Document Type: Article

References (57)

1. Anon. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
2. Barista I, Romaguera JE, Cabanillas F. Mantle cell lymphoma. Lancet Oncol. 2001;2:141-148.
3. Harris NL. Mantle cell lymphoma. J Clin Oncol. 1994;12:876-877.
4. Tolksdorf G, Stein H, Lennert K. Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes). Br J Cancer. 1980;41:168-182.
5. Weisenburger DD, Armitage JO. Mantle cell lymphoma: an entity comes of age. Blood. 1996;87:4483-4494.
6. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067-2078.
7. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82:567-575.
8. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075-1082.
9. Norton AJ, Matthews J, Pappa V, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol. 1995;6:249-256.
10. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 1996;14:1269-1274.
11. Zucca E, Fontana S, Roggero E, Pedrinis E, Pampallona S, Cavalli F. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution. Leuk Lymphoma. 1994;13:105-110.
12. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A. 1991;88:9638-9642.
13. Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 1984;224:1403-1406.
14. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993;7:1559-1571.
15. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124-2130.
16. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487-3495.
17. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 1998;91:2977-2984.
18. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619-626.
19. Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood. 15;99:4554-4561.
20. Au WY, Gascoyne RD, Viswanatha DS, Connors JM, Klasa RJ, Horsman DE. Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. Leuk Lymphoma. 2002;43:783-791.
21. Cuneo A, Bigoni R, Rigolin GM, et al. Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features. Blood. 1999;93:1372-1380.
22. Wlodarska I, Pittaluga S, Hagemeijer A, De Wolf-Peeters C, Van Den Berghe H. Secondary chromosome changes in mantle cell lymphoma. Haematologica. 1999;84:594-599.
23. Allen JE, Hough RE, Goepel JR, et al. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol. 2002;116:291-298.
24. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 1999;93:4365-4374.
25. Bentz M, Plesch A, Bullinger L, et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2000;27:285-294.
26. Martinez-Climent JA, Vizcarra E, Sanchez D, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood. 2001;98:3479-3482.
27. Monni O, Oinonen R, Elonen E, et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer. 1998;21:298-307.
28. Bentz M, Plesch A, Stilgenbauer S, Döhner H, Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer. 1998;21:172-175.
29. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer. 1997;20:399-407.
30. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20:207-211.
31. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994;83:1165-1173.
32. Schwänen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A. 2004;101:1039-1044.
33. Wessendorf S, Fritz B, Wrobel G, et al. Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. Lab Invest. 2002;82:47-60.
34. Lichter P, Bentz M, Du Manoir S, Joos S. Comparative genomic hybridization. In: Verma R, Babu A, eds. Human chromosomes. New York, NY: McGraw-Hill; 1995:191-210.
35. du Manoir S, Schröck E, Bentz M, et al. Quantitative analysis of comparative genomic hybridization. Cytometry. 1995;19:27-41.
36. Lichter P, Bentz M, Joos S. Detection of chromosomal aberrations by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. Methods Enzymol. 1995;254:334-359.
37. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;47:457-481.
38. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc (A). 1972;135:185-192.
39. Kienle D, Kröber A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102:3003-3009.
40. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
41. Hamaguchi M, Meth JL, von Klitzing C, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A. 2002;99:13647-13652.
42. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164-168.
43. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61:2409-2412.
44. Gruszka-Westwood AM, Atkinson S, Summersgill BM, et al. Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. Genes Chromosomes Cancer. 2002;33:206-212.
45. Lukas J, Jadayel D, Bartkova J, et al. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene. 1994;9:2159-2167.
46. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-11q23.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A. 1996;93:11837-11841.
47. Schaffner C, Idler I, Stilgenbauer S, Döhner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A. 2000;97:2773-2778.
48. Stilgenbauer S, Winkler D, Ott G, et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood. 1999;94:3262-3264.
49. Monni O, Zhu Y, Franssila K, et al. Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma. Br J Haematol. 1999;104:665-671.
50. Arai Y, Hosoda F, Kobayashi H, et al. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood. 1997;89:3936-3944.
51. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
52. Bullrich F, Veronese ML, Kitada S, et al. Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood. 1996;88:3109-3115.
53. Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics. 1997;42:369-377.
54. Bouyge-Moreau I, Rondeau G, Avet-Loiseau H, et al. Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3. Genomics. 1997;46:183-190.
55. Corcoran MM, Rasool O, Liu Y, et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood. 1998;91:1382-1390.
56. Stilgenbauer S, Nickolenko J, Wilhelm J, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene. 1996;16:1691-1697.
57. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.